A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

Trial Profile

A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2018

At a glance

  • Drugs Enzalutamide (Primary) ; Bicalutamide
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms TERRAIN
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 10 Feb 2018 Results of post hoc analysis evaluating the hepatic effects of enzalutamide versus comparators in controlled castration-resistant prostate cancer trials (NCT0121299; NCT00974311; NCT01664923; NCT01288911) presented at the 2018 Genitourinary Cancers Symposium
    • 15 Dec 2017 This study has been completed in Germany according to European Clinical Trials Database record.
    • 04 Dec 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top